PHARMACY

Finding fraud: Tracking, technology and tips for pharmacies

Recent Congressional bills demonstrate the government’s proposed intent to crack down on the U.S. opioid epidemic. But as anyone in our industry knows, addiction is a multi-faceted problem that requires significant investments of time, money, energy, compassion and creative thinking.

When it comes to managing the dispensing of controlled substances, pharmacies are truly the last line of defense. State boards, law enforcement, and prescribers all shoulder huge responsibilities for executing prescription vigilance, but the potential for fraud is a real and ever-present problem for the retail pharmacies. Prescription fraud takes numerous forms, and the ways offenders will try to beat the system are numerous.

While the opioid crisis demands that pharmacists look once, twice, even three times at possible offenders — whether patients or prescribers — they also have a responsibility to regularly serve patients who have legitimate medication needs. Community dynamics have shifted significantly in that great distances often separate work and home lives, as well as residences of family members. It used to be that one pharmacy could serve an entire family seamlessly, and the pharmacist knew his or her customers well, using that knowledge and relationships as primary screening tools for substance abuse. Today, simple geography has changed that, making pharmacies more ubiquitous and adding complexity to the screening and distribution process.

Many patients renew scripts through an automated phone service, and simply pick up the bag without much staff interaction. Certainly, technology has made this process easier and less time-consuming for patients. Technology, in similar ways, can make it easier for pharmacy teams with the ability to analyze data about prescriptions and help set up alerts when possible fraud or compliance issues arise. When pharmacists aren’t able to secure trust based on a personal relationship, a solution that helps them understand the system’s most important data elements is the next best thing.

Furthermore, through its suspicious order monitoring program, the DEA expects retail pharmacies to carefully monitor the flow of controlled substances at their locations. There are numerous rules and regulations, but the intent is clear: retail pharmacies must have transparency and understanding about their customers, prescribers and distributors, especially in the context of its peer groups.

Prescription drug monitoring programs of the National Alliance for Model State Drug Laws provide a state-wide electronic database to collect data on certain controlled substances, but unfortunately aren’t typically part of the pharmacy’s primary daily workflow. Not only is it cumbersome to access the data, there are often lag times, which limit its application as a true contributory database. The industry requires a real-time prescription database that seamlessly integrates with workflow operations so pharmacists can help mitigate the controlled substance abuse problem rampant in our country.

Implementing a true contributory database solution is a critical step in understanding and overcoming the prescription opioid epidemic. At the same time, situational context discussed above still holds power to control fraud and abuse. While pharmacists may not have personal relationships with every customer, there are situations and circumstances surrounding the acquiring of certain medications that should be cause for concern.

The National Association of Boards of Pharmacy and the Anti-Diversion Industry Working Group, made up of pharmaceutical manufacturers and distributors, highlighted “Red Flags,” or warning signs of abuse or diversion. Be on the lookout any time a group of patients approaches the counter together: Are they all holding prescriptions for the same drug … or from the same provider? Be cautious about location of the provider: it should be in relatively close proximity to the pharmacy and patient. Ask for an explanation if the details do not add up.

It’s generally considered suspicious if a patient forgoes using insurance and requests to pay cash only for certain medication, especially controlled substances. The large majority of Americans have some form of insurance and prescription plan. Some offenders prefer late hours, hoping to sneak in under the radar of an unfamiliar pharmacist, or alternatively, come during the busiest times of day so the pharmacist will rush the request through the system. Be aware of customers who are exhibiting abnormal patterns of speaking, are afraid to make eye contact (or hiding small pupils) or seem anxious or upset. Pharmacists are customer-facing for a very important reason—they must pay attention to physical and behavioral warning signs of potential abuse.

Pharmacists should also be on the lookout for group scripts combining medications that work to intensify the drugs’ impact, such as opioids, benzodiazepines, and muscle relaxers. Also pay close attention to the provider’s credentials, specialty and condition for which the medications are being prescribed. A key question: does all this fit together and make sense as part of a treatment plan? Stay aware of local news reports about pain clinics or other prescribers under investigation for drug diversion.

Obviously, prescriptive authority must be confirmed from the outset. Fraud via stolen prescription pads is still common, as is tampering with quantities and refill amounts. Ask yourself: Does this drug make most sense in the quantity of 100, or 10? Thankfully, secure E-prescribing is becoming much more prevalent, reducing the number of altered paper prescriptions pharmacists see.

Fraud approaches the pharmacy counter every single day. Use the technology available to you to flag unusual patterns of prescribing. Use that gut instinct that tells you something is “off” with a patient or a prescriber. Pharmacists have every right and a corresponding responsibility to use professional judgement in filling prescriptions for controlled substances. Let’s all be part of the solution. Our future depends on it.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

FDA approves Breckenridge’s generic Baraclude

BY DSN STAFF

Breckenridge Pharmaceutical has received Food and Drug Administration approval for its generic Baraclude (entecavir). The drug is indicated as a treatment for chronic hepatitis B.

Breckenridge’s generic Baraclude will be available in 0.5- and 1-mg dosage strengths. The drug will be manufactured by RA Chem Pharma, with Breckenridge as the exclusive U.S. distributor.

The generic and branded versions of Baraclude had combined U.S. sales of roughly $95.9 million for 12 months ended January 2018, according to IQVIA data.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

Impax shareholders green-light Amneal merger

BY David Salazar

Impax Labs has cleared a hurdle in its pending acquisition by Amneal Pharmaceuticals. The Bridgewater, N.J.-based company’s shareholders have overwhelmingly approved the combination, with 99% of votes cast in favor of the all-stock transaction.

“We appreciate the strong support we have received from Impax shareholders for our transformational combination with Amneal,” Impax president and CEO Paul Bisaro said. “Today’s approval represents an important milestone in the process to combine our two organizations and create a diversified pharmaceutical company with stronger capabilities and greater resources. We look forward to continuing to work closely with Amneal to complete the transaction so we can provide greater access to safe and affordable medicine for patients, open up new opportunities for our employees and deliver enhanced value for shareholders.”

Impax shareholders will own 25% of the combined company, which will be helmed by Allergan veteran Robert Stewart. Bisaro will be the company’s executive chairman, while Amneal’s Chirag and Chintu Patel will be its co-chairman. Ahead of the merger’s completion, Amneal also has brought Andrew Boyer, former head of Teva’s North American generics operations, onboard as executive vice president of commercial operations.

Impax said that it expects the deal to close in the second quarter of this year, pending regulatory approval and satisfaction of customary closing conditions.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?